Fase 1 Study to Evaluate the Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.
Latest Information Update: 17 Oct 2019
At a glance
- Drugs PRO 155 (Primary)
- Indications Cataracts; Ocular inflammation
- Focus Therapeutic Use
- 09 May 2019 Status changed from active, no longer recruiting to completed.
- 29 Feb 2012 New trial record